PerspectiveChromatin Therapeutics

Cancer Drug Discovery Faces the FACT

Science Translational Medicine  10 Aug 2011:
Vol. 3, Issue 95, pp. 95ps34
DOI: 10.1126/scitranslmed.3002822

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules—curaxins—that inhibit tumor cell growth and division. The curaxins’ mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.

Footnotes

  • Citation: G. F. Draetta, R. A. DePinho, Cancer Drug Discovery Faces the FACT. Sci. Transl. Med. 3, 95ps34 (2011).

View Full Text